Cobas HBV Test

FDA premarket approval P150014 · Hepatitis Viral B DNA Detection

PMA numberP150014

Approval

Applicant
Roche Molecular Systems, Inc.
Received
April 24, 2015
Decision date
October 14, 2015 (APRL)
Supplements
57, latest October 17, 2025
Product code
MKT – Hepatitis Viral B Dna Detection

Official FDA PMA record

Approval order statement

APPROVAL FOR THE COBAS HBV. THIS DEVICE IS INDICATED FOR: COBAS HBV IS AN IN VITRO NUCLEIC ACID AMPLIFICATION TEST FOR THE QUANTITATION OF HEPATITIS B VIRUS (HBV) DNA IN HUMAN EDTA PLASMA OR SERUM OF HBV-INFECTED INDIVIDUALS. THIS TEST IS INTENDED FOR USE AS AN AID IN THE MANAGEMENT OF PATIENTS WITH CHRONIC HBV INFECTION UNDERGOING ANTI-VIRAL THERAPY. THE TEST CAN BE USED TO MEASURE HBV DNA LEVELS AT BASELINE AND DURING TREATMENT TO AID IN ASSESSING RESPONSE TO TREATMENT. THE RESULTS FROM COBAS HBV MUST BE INTERPRETED WITHIN THE CONTEXT OF ALL RELEVANT CLINICAL AND LABORATORY FINDINGS.THE COBAS HBV IS NOT INTENDED FOR USE AS A SCREENING TEST FOR THE PRESENCE OF HBV IN BLOOD OR BLOOD PRODUCTS OR AS A DIAGNOSTIC TEST TO CONFIRM THE PRESENCE OF HBV INFECTION.